Clinical Cancer Research · 2024 · 13 citations · 31 references
MedicineMolecular BiologyOncologyMolecular OncologyNeoplasiaOncogenesCancer GenomicsMalignant NeoplasmsMolecular Classification Of TumorsOncogenic Signaling PathwaysSingle-cell Rna Sequencing AnalysisTumor ClassificationLarge Cell Neuroendocrine CarcinomaNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentSingle-cell Cancer GenomicsSingle-cell Rna SequencingSingle-cell Tumor GenomicsSmarcb1-deficient TumorsTp53 Mutations
PURPOSE: Large cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine malignancy that, like small cell lung cancer (SCLC), is associated with the absence of druggable oncogenic drivers and dismal prognosis. In contrast to SCLC, however, there is little evidence to guide optimal treatment strategies, which are often adapted from SCLC and non-small cell lung cancer approaches. EXPERIMENTAL DESIGN: To better define the biology of LCNEC, we analyzed cell line and patient genomic data and performed IHC and single-cell RNA sequencing of core needle biopsies from patients with LCNEC and preclinical models. RESULTS: In this study, we demonstrate that the presence or absence of YAP1 distinguishes two subsets of LCNEC. The YAP1-high subset is mesenchymal and inflamed and is characterized, alongside TP53 mutations, by co-occurring alterations in CDKN2A/B and SMARCA4. Therapeutically, the YAP1-high subset demonstrates vulnerability to MEK- and AXL-targeting strategies, including a novel preclinical AXL chimeric antigen receptor-expressing T cell. Meanwhile, the YAP1-low subset is epithelial and immune-cold and more commonly features TP53 and RB1 co-mutations, similar to those observed in pure SCLC. Notably, the YAP1-low subset is also characterized by the expression of SCLC subtype-defining transcription factors, especially ASCL1 and NEUROD1, and as expected, given its transcriptional similarities to SCLC, exhibits putative vulnerabilities reminiscent of SCLC, including delta-like ligand 3 and CD56 targeting, as is with novel preclinical delta-like ligand 3 and CD56 chimeric antigen receptor-expressing T cells, and DNA damage repair inhibition. CONCLUSIONS: YAP1 defines distinct subsets of LCNEC with unique biology. These findings highlight the potential for YAP1 to guide personalized treatment strategies for LCNEC.
31
Ethan Cerami, Jianjiong Gao, Uğur Doğrusöz et al. · Cancer Discovery · 2012 · 18.4K citations · Full text
Medicine, Bioinformatics, Oncology +15
Integrated analysis of multimodal single-cell data
Yuhan Hao, Stephanie Hao, Erica Andersen‐Nissen et al. · Cell · 2021 · 16K citations · Full text
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina, Giordano Caponigro, Nicolas Stransky et al. · Nature · 2012 · 8.5K citations
Medicine, Oncology, Pharmacology +15
Massively parallel digital transcriptional profiling of single cells
Grace Zheng, Jessica M. Terry, Phillip Belgrader et al. · Nature Communications · 2017 · 7.8K citations · Full text
Spatial reconstruction of single-cell gene expression data
Rahul Satija, Jeffrey A. Farrell, David Gennert et al. · Nature Biotechnology · 2015 · 7.7K citations · Full text